Lastly, since VP-MCC immune evasion to MCPyV TAg specific CD8+ can occur in VP-MCC tumors treated with checkpoint inhibitors and HLA class I restricted transduced TCRs (14), the ACT of VP-MCC-specific CD4+ T cell could be beneficial in reversing such evasion. This evidence concerns the gene CD4 and Merkel cell skin cancer.